196 related articles for article (PubMed ID: 21571974)
1. Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3.
Syrjänen K; Shabalova I; Naud P; Derchain S; Sarian L; Kozachenko V; Zakharchenko S; Roteli-Martins C; Nerovjna R; Longatto-Filho A; Kljukina L; Tatti S; Branovskaja M; Branca M; Grunjberga V; Erzen M; Juschenko A; Hammes LS; Costa S; Podistov J; Syrjänen S; ; ;
Int J STD AIDS; 2011 May; 22(5):263-72. PubMed ID: 21571974
[TBL] [Abstract][Full Text] [Related]
2. Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Syrjänen K; Shabalova I; Sarian L; Naud P; Longatto-Filho A; Derchain S; Kozachenko V; Zakharchenko S; Roteli-Martins C; Nerovjna R; Kljukina L; Tatti S; Branovskaja M; Branca M; Grunjberga V; Erzen M; Juschenko A; Serpa Hammes L; Podistov J; Costa S; Syrjänen S; ;
Eur J Gynaecol Oncol; 2012; 33(1):5-14. PubMed ID: 22439398
[TBL] [Abstract][Full Text] [Related]
3. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts.
Syrjänen K; Shabalova I; Naud P; Kozachenko V; Derchain S; Zakharchenko S; Roteli-Martins C; Nerovjna R; Longatto-Filho A; Kljukina L; Tatti S; Branovskaja M; Hammes LS; Branca M; Grunjberga V; Erzen M; Sarian LO; Juschenko A; Costa S; Podistov J; Syrjänen S;
Int J Gynecol Cancer; 2009 Jul; 19(5):934-42. PubMed ID: 19574788
[TBL] [Abstract][Full Text] [Related]
4. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
5. Molecular progression to cervical precancer, epigenetic switch or sequential model?
Nedjai B; Reuter C; Ahmad A; Banwait R; Warman R; Carton J; Boer S; Cuzick J; Lorincz AT
Int J Cancer; 2018 Oct; 143(7):1720-1730. PubMed ID: 29679470
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.
Wang SS; Zuna RE; Wentzensen N; Dunn ST; Sherman ME; Gold MA; Schiffman M; Wacholder S; Allen RA; Block I; Downing K; Jeronimo J; Carreon JD; Safaeian M; Brown D; Walker JL
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):113-20. PubMed ID: 19124488
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2.
Okadome M; Saito T; Tanaka H; Nogawa T; Furuta R; Watanabe K; Kita T; Yamamoto K; Mikami M; Takizawa K;
J Obstet Gynaecol Res; 2014 Feb; 40(2):561-9. PubMed ID: 24147758
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort.
Syrjänen S; Naud P; Sarian L; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Costa S; Syrjänen K
Virchows Arch; 2009 Dec; 455(6):505-15. PubMed ID: 19908064
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
12. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.
Insinga RP; Perez G; Wheeler CM; Koutsky LA; Garland SM; Leodolter S; Joura EA; Ferris DG; Steben M; Hernandez-Avila M; Brown DR; Elbasha E; Muñoz N; Paavonen J; Haupt RM;
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):287-96. PubMed ID: 21300618
[TBL] [Abstract][Full Text] [Related]
13. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
14. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women.
Hosaka M; Fujita H; Hanley SJ; Sasaki T; Shirakawa Y; Abiko M; Kudo M; Kaneuchi M; Watari H; Kikuchi K; Sakuragi N
Int J Cancer; 2013 Jan; 132(2):327-34. PubMed ID: 22729477
[TBL] [Abstract][Full Text] [Related]
15. Investigating Diagnostic Problems of CIN1 and CIN2 Associated With High-risk HPV by Combining the Novel Molecular Biomarker PanHPVE4 With P16INK4a.
van Baars R; Griffin H; Wu Z; Soneji YJ; van de Sandt M; Arora R; van der Marel J; Ter Harmsel B; Jach R; Okon K; Huras H; Jenkins D; Quint W; Doorbar J
Am J Surg Pathol; 2015 Nov; 39(11):1518-1528. PubMed ID: 26379150
[TBL] [Abstract][Full Text] [Related]
16. Human papilloma virus testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia.
Almog B; Gamzu R; Kuperminc MJ; Levin I; Fainaru O; Niv J; Bar-Am A
Gynecol Oncol; 2003 Mar; 88(3):345-50. PubMed ID: 12648585
[TBL] [Abstract][Full Text] [Related]
17. Comparison of human papillomavirus distribution in cytologic subgroups of low-grade squamous intraepithelial lesion.
Zuna RE; Wang SS; Schiffman M; Solomon D
Cancer; 2006 Oct; 108(5):288-97. PubMed ID: 16952155
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.
Guan P; Howell-Jones R; Li N; Bruni L; de Sanjosé S; Franceschi S; Clifford GM
Int J Cancer; 2012 Nov; 131(10):2349-59. PubMed ID: 22323075
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
20. Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2.
Pajtler M; Milicić-Juhas V; Milojković M; Topolovec Z; Curzik D; Mihaljević I
Coll Antropol; 2010 Mar; 34(1):81-6. PubMed ID: 20432737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
